Rizwana F. Sproule is VP at Kite Pharma, Inc. (KITE). They have made 4 open-market trades across 1 company since 2015, most recently 2016-03-15.
CIK 0001510580
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KITE | 10,899 | $2.0M |
Shares reported on the most recent Form 4, priced at the 2016-03-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KITE | SELL | 2016-03-15 | 2016-03-17 | $45.20 | $737K | -1.5% | +6.8% | +17.1% |
| KITE | SELL | 2016-02-17 | 2016-02-19 | $45.07 | $858K | +9.9% | -6.4% | -7.1% |
| KITE | SELL | 2016-01-15 | 2016-01-19 | $55.27 | $281K | -11.8% | -13.3% | -11.0% |
| KITE | SELL | 2016-01-15 | 2016-01-19 | $55.49 | $531K | -11.8% | -13.3% | -11.0% |
| KITE | SELL · 10b5-1 | 2015-12-15 | 2015-12-17 | $63.76 | $610K | -16.7% | -9.2% | -27.0% |
| KITE | SELL · 10b5-1 | 2015-11-16 | 2015-11-18 | $78.13 | $748K | -16.7% | +2.4% | -25.8% |
| KITE | SELL · 10b5-1 | 2015-10-15 | 2015-10-19 | $62.58 | $599K | -16.7% | +2.4% | -9.2% |
| KITE | SELL · 10b5-1 | 2015-09-15 | 2015-09-17 | $64.36 | $616K | -16.7% | +2.4% | +2.4% |
| KITE | SELL · 10b5-1 | 2015-08-17 | 2015-08-19 | $60.88 | $582K | -16.7% | +2.4% | +2.4% |
| KITE | SELL · 10b5-1 | 2015-07-15 | 2015-07-20 | $71.90 | $688K | -16.7% | +2.4% | +2.4% |
| KITE | SELL · 10b5-1 | 2015-06-15 | 2015-06-17 | $56.98 | $545K | -16.7% | +2.4% | +2.4% |
| KITE | SELL · 10b5-1 | 2015-05-15 | 2015-05-19 | $50.16 | $480K | -16.7% | +2.4% | +2.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.